(NASDAQ: FBLG) Fibrobiologics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.44%.
Fibrobiologics's earnings in 2026 is -$18,646,000.On average, 6 Wall Street analysts forecast FBLG's earnings for 2026 to be -$16,891,921, with the lowest FBLG earnings forecast at -$19,210,420, and the highest FBLG earnings forecast at -$12,065,658. On average, 6 Wall Street analysts forecast FBLG's earnings for 2027 to be -$18,446,600, with the lowest FBLG earnings forecast at -$25,172,274, and the highest FBLG earnings forecast at -$11,355,913.
In 2028, FBLG is forecast to generate -$19,649,786 in earnings, with the lowest earnings forecast at -$33,121,414 and the highest earnings forecast at -$13,485,147.